company background image

Diagonal Bio OM:DIABIO Stock Report

Last Price


Market Cap







18 Mar, 2023


Company Financials

DIABIO Stock Overview

About the company

Diagonal Bio AB (publ) operates as a biotechnology company in Sweden. It is involved in developing the Panviral platform for detecting and diagnosing small sections of pathogen genomes, such as viruses, bacteria, and fungi. The company was incorporated in 2020 and is headquartered in Lund, Sweden.

Snowflake Analysis

DIABIO fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health3/6

My Notes

Capture your thoughts, links and company narrative

Diagonal Bio AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Diagonal Bio
Historical stock prices
Current Share Pricekr0.47
52 Week Highkr8.52
52 Week Lowkr0.42
1 Month Change-11.04%
3 Month Change-45.17%
1 Year Change-90.64%
3 Year Changen/a
5 Year Changen/a
Change since IPO-96.90%

Recent News & Updates

Recent updates

Shareholder Returns

DIABIOSE BiotechsSE Market

Return vs Industry: DIABIO underperformed the Swedish Biotechs industry which returned -4.9% over the past year.

Return vs Market: DIABIO underperformed the Swedish Market which returned -16.2% over the past year.

Price Volatility

Is DIABIO's price volatile compared to industry and market?
DIABIO volatility
DIABIO Average Weekly Movement15.7%
Biotechs Industry Average Movement7.6%
Market Average Movement6.6%
10% most volatile stocks in SE Market12.0%
10% least volatile stocks in SE Market4.0%

Stable Share Price: DIABIO is more volatile than 90% of Swedish stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: DIABIO's weekly volatility has decreased from 29% to 16% over the past year, but is still higher than 75% of Swedish stocks.

Diagonal Bio AB (publ) Fundamentals Summary

How do Diagonal Bio's earnings and revenue compare to its market cap?
DIABIO fundamental statistics
Market Capkr16.39m
Earnings (TTM)-kr16.16m
Revenue (TTM)kr3.71m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DIABIO income statement (TTM)
Cost of Revenuekr1.65m
Gross Profitkr2.05m
Other Expenseskr18.22m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date


Earnings per share (EPS)-0.46
Gross Margin55.42%
Net Profit Margin-436.16%
Debt/Equity Ratio0%

How did DIABIO perform over the long term?

See historical performance and comparison